A New Option for High-Risk Myeloma: Dual BiTE Therapy Explained

In this video, Precision Oncology Specialist, Alex Rolland, and Advocacy Specialist, Michelle Morand, break down exciting new data from the RedirecTT-1 trial, where two Bi-Specific T-cell Engagers (BiTEs) were combined to treat heavily pre-treated patients with true extramedullary disease.

Drug-resistant extramedullary multiple myeloma (EMD) is one of the most aggressive and difficult-to-treat forms of myeloma.

Watch this video to learn:
• What extramedullary multiple myeloma is, and why it’s so challenging
• How BiTEs work
• The difference between IgG2 and IgG4 BiTE antibodies
• The response rates, progression-free survival (PFS), and overall survival (OS) data

If you or a loved one is navigating relapsed or drug-resistant multiple myeloma, understanding emerging therapies like BiTE combinations is critical.

***

Would you like further support with your cancer care? Let us help you and your doctor to access the newest, leading-edge diagnostics and treatments for your care.

🌿 Join our Free Daily Drop-in Zoom Calls with Michelle: https://lp.constantcontactpages.com/cu/BN9VJg9/dailydropinzoomcalls

Book a free Cancer Care Consultation with our team: https://www.ctoam.com/free-strategy-session

Register for a Precision Second Opinion & Complete Treatment Options Review with expert Alex Rolland: https://www.ctoam.com/consultation

Learn more about Alex: https://alexrolland.com 🧬

Download CTOAM’S Free Ebook Here: https://www.ctoam.com/ebook/ 📘

Join our (free) "Cancer Just the Facts" online program:
👉 https://cancerjustthefacts.com/
Get hundreds of free resources on Precision Cancer Medicine and access to our weekly Zoom calls with cancer experts.

***

CTOAM is a worldwide, Canadian-based personalized cancer care and precision oncology service specializing in getting our client's rapid access to the best possible cancer treatment available for their form of cancer, while assisting their physicians in having the most current data from which to make confident treatment decisions on your behalf.

We facilitate access to peer-reviewed, science-based precision diagnostics such as PET/CT scans, liquid biopsy (blood-based genetic tests) and detailed genetic panels. We use these leading diagnostic tools, combined with a thorough and personalized research review, as our team explores the most advanced scientific data available today to find the best options for you.

Other ways to stay in touch with CTOAM:

Facebook: https://www.facebook.com/CancerTreatmentOptionsandManagement/
LinkedIn: https://www.linkedin.com/company/ctoam
Twitter: https://twitter.com/CTOAM
Blog: https://research.ctoam.com/
LinkedIn (Liquid Biopsy Labs): https://www.linkedin.com/company/13063544
LBL Twitter: https://twitter.com/LiquidBiopsyNow
Disclaimer:

Please understand that these videos are meant for educational purposes only. These videos are not intended to diagnose or be used as treatment advice. Viewers are encouraged to speak with their doctor or healthcare professionals for medical advice and before making any changes to their healthcare based on this information. All statements made in this video regarding medical treatments and health conditions are sourced and have been approved by the U.S. Food and Drug Administration (FDA). Watching this video is not a substitute for professional medical advice or a diagnosis.

Видео A New Option for High-Risk Myeloma: Dual BiTE Therapy Explained канала The Cancer Guy